$ALEC News

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Alector Launches Up To $125M At-The-Market Common Stock Offering Through TD Cowen

Alector Q1 EPS $(0.21) Beats $(0.35) Estimate, Sales $1.046M Miss $6.207M Estimate

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates

GSK Juggles Alzheimer’s Setback And Leadership Shift With Product Progress

How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

Discovering Middle East's Undiscovered Gems This April 2026

Cantor Fitzgerald Upgrades Alector to Overweight

Undiscovered Gems in the Middle East for March 2026

Why The Narrative Around Alector (ALEC) Is Shifting With Its BBB Shuttle Focus

Alector Files Prospectus To Offer Up To $400M In Common Stock

Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Alector shares are trading higher after BTIG upgraded the stock from Neutral to Buy rating and announced a $6 price target.

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

BTIG Upgrades Alector to Buy, Announces $6 Price Target

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript